<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00851929</url>
  </required_header>
  <id_info>
    <org_study_id>17747</org_study_id>
    <nct_id>NCT00851929</nct_id>
  </id_info>
  <brief_title>Ambrisentan (Letairis) for Sarcoidosis Associated Pulmonary Hypertension</brief_title>
  <official_title>Ambrisentan (Letairis) for Sarcoidosis Associated Pulmonary Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of South Carolina</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypothesis: Ambrisentan (Letairis ®) is safe and effective in treating pulmonary hypertension
      in patients with Sarcoidosis
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Endpoint: Change in 6 minute walk distance.

      Secondary Endpoints:

        -  Safety

             -  Oxygen saturation at rest and with exercise

             -  Hospitalization

             -  Mortality

        -  WHO functional class

        -  Quality of life as measured by

             -  Short-form 36

             -  Sarcoidosis Health Questionnaire

        -  Dyspnea as measured by

             -  Borg Dyspnea Index

             -  St. George Respiratory Questionnaire

        -  Sarcoidosis activity as measured by the

             -  STAI sarcoidosis instrument (33)

             -  Prednisone dose

        -  Pulmonary function

             -  Forced vital capacity (FVC)

             -  Diffusion (DLCO)

        -  Endothelin-1 levels

             -  Bronchoalveolar lavage

             -  Plasma

        -  B-type natruetic peptide

        -  Inflammatory and fibrotic mediators (IL-2, IL-6, IL-12, IL-18, IL-23, TNF-α) in BALF

        -  Compliance with treatment

        -  Time to clinical worsening (defined by the initiation of ambrisentan treatment to the
           first occurrence of death, lung transplantation, hospitalization for pulmonary arterial
           hypertension, arterial septostomy, a change in chronic prostanoid or sildenafil
           treatment due to protocol defined worsening criteria or study withdrawal due to
           additional of other clinically approved PAH therapeutic agents)
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2008</start_date>
  <completion_date type="Anticipated">June 2010</completion_date>
  <primary_completion_date type="Anticipated">December 2009</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in 6 minute walk distance.</measure>
    <time_frame>4 months of therapy</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Sarcoidosis</condition>
  <condition>Pulmonary Hypertension</condition>
  <arm_group>
    <arm_group_label>sarcoidosis associated pulmonary hypertension</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>sarcoidosis associated pulmonary hypertension</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ambrisentan</intervention_name>
    <description>ambrisentan 5 mg/day for month month, then 10 mg/day for 3 additional months</description>
    <arm_group_label>sarcoidosis associated pulmonary hypertension</arm_group_label>
    <other_name>Letairis</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Biopsy proven sarcoidosis

          -  Mean pulmonary artery pressure &gt; 25 mmHg at rest and greater than 30 mmHg with
             exercise by right heart catheterization within 1 year prior to entry into study

          -  Pulmonary capillary wedge pressure ≤ 15 mmHg

          -  PVR values &gt;3.0 Woods units

          -  Forced vital capacity (FVC) &gt;40%

          -  WHO functional class II or III

          -  Stable sarcoidosis treatment regimen for three months prior to entry into study

          -  6 minute walk distance between 150-450 meters

          -  Stable dose of antihypertensive medications

          -  On no other medication to treat PAH (sildenafil, tadalafil, vardenafil, treprostinil,
             epoprostenol, iloprost, bosentan, sitaxsentan) within one month prior to enrollment
             and during duration of the study

          -  Non-pregnant females

        Exclusion Criteria:

          -  Exercise limitation related to a non-cardiopulmonary reason (e.g. arthritis)

          -  Severe systemic hypertension &gt; 170/95

          -  Patients with congestive heart failure (left ventricular dysfunction) or primary right
             ventricular dysfunction

          -  Anticipation by the investigator for escalation in sarcoidosis treatment during the
             course of the study

          -  Pulmonary hypertension related to etiology other than sarcoidosis (i.e. HIV,
             scleroderma, etc.)

          -  Use within 1 month of an endothelin receptor antagonists (bosentan, sitaxsentan).

          -  WHO functional class IV status

          -  Patients with significant left ventricular dysfunction

          -  Significant liver dysfunction not due to sarcoidosis.

          -  Patients with severe other organ disease felt by investigators to impact on survival
             during the course of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Marc A Judson, MD</last_name>
    <phone>843-697-7272</phone>
    <email>judsonma@musc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nicole Craft</last_name>
    <phone>843-792-4557</phone>
    <email>craftn@musc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Northwestern University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Peter Sporn, MD</last_name>
      <email>p-sporn@northwestern.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of North Carolina Medical Center</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>James Ford, MD</last_name>
      <email>hford@unch.unc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical Univerrsity of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29466</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc A Judson, MD</last_name>
      <email>judsonma@musc.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 24, 2009</study_first_submitted>
  <study_first_submitted_qc>February 25, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 26, 2009</study_first_posted>
  <last_update_submitted>February 25, 2009</last_update_submitted>
  <last_update_submitted_qc>February 25, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 26, 2009</last_update_posted>
  <responsible_party>
    <name_title>Marc A. Judson, M.D.</name_title>
    <organization>Medical University of South Carolina</organization>
  </responsible_party>
  <keyword>sarcoidosis</keyword>
  <keyword>pulmonary hypertension</keyword>
  <keyword>dyspnea</keyword>
  <keyword>sarcoidosis associated pulmonary hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Sarcoidosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ambrisentan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

